Trade Filings
Managers Stocks Filings Superinvestors
Signals Institutional Buying Institutional Selling Insider Activity 13D & 13G Watch Sector Rotation
Tools Stock Screener Manager Screener Compare Managers Consensus Baskets All Research Tools Data API
Learn & AI Learn Ask the Data AI Agents
News ★ Saved
About About us Methodology Contact Disclaimer
Reader
DATA PLANS

Historical data downloads — coming with accounts.

API GATEWAY

Free read-only JSON access to the site's cached data.

Dark mode

🧭 Guided View
New to markets — prices, yields, YTD, market cap? We explain every term as you browse, in plain English. Same data, with the help built in.

⚡ Expert View
You already know the market. Just the data — clean, fast and compact, with no extra explanations. This is the default view.

Interface language
Security record · archived quarter

ANRO

Alto Neuroscience, Inc. · Healthcare · Biotechnology

36.53 +0.6% mkt cap $1.28B quote delayed (FMP) · as of Aug 26 21:08 UTC — separate from filing data below

Q2 2026 Q1 2026 Q4 2025 Q3 2025 Q2 2025 Q1 2025 Q4 2024 Q3 2024
8Tracked holders
+2Δ holders
5.27MShares held
$22.30MReported value
+2New positions
−0Exits
Strongly Rising Conviction score 82/100 2 quarters of rising tracked shares ●●○○○○ How these are computed → Explain this at the Research Desk →

Momentum inputs (comparable managers): holder breadth +30.0% · share flow +30.0% · net new positions +20.0%formula
Broad accumulation — rising shares across more holders

All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q4 2024

Ownership over time
QuarterHoldersΔSharesReported valueNewExits
Q2 2026 56 +2 11.55M $304.50M +10 −8
Q1 2026 55 +7 8.39M $188.63M +8 −1
Q4 2025 48 +2 8.42M $149.83M +3 −1
Q3 2025 15 +1 4.77M $19.16M +1
Q2 2025 12 0 4.77M $10.50M +1 −1
Q1 2025 9 +1 3.54M $7.65M +2 −1
Q4 2024 8 +2 5.27M $22.30M +2
Q3 2024 5 0 2.33M $26.66M +2 −2
Q2 2024 5 1.98M $21.15M
Holder count
Who holds it · Q4 2024
#ManagerSharesΔ sharesValueTheir weightHeld
1 Point72 Asset Management 1.69M +73.1% $7.16M 0.0% ▲ Add 3 SEC ↗
2 Citadel Advisors 975.99K New $4.13M 0.0% New 1 SEC ↗
3 T. Rowe Price 844.82K +4.5% $3.58M 0.0% ▲ Add 3 SEC ↗
4 T. Rowe Price 844.82K +4.5% $3.58M 0.0% ▲ Add 3 SEC ↗
5 Marshall Wace 837.37K New $3.54M 0.0% New 1 SEC ↗
6 Geode Capital Management (passive) 472.66K +0.6% $2.00M 0.0% ▲ Add 3 SEC ↗
7 Geode Capital Management (passive) 472.66K +0.6% $2.00M 0.0% ▲ Add 3 SEC ↗
8 State Street Global Advisors (passive) 339.71K $1.44M 0.0% n/c 1 SEC ↗
9 Wellington Management 77.15K +27.2% $326,328 0.0% ▲ Add 2 SEC ↗
10 Wellington Management 77.15K +27.2% $326,328 0.0% ▲ Add 2 SEC ↗
11 Two Sigma Investments 30.70K +137.2% $129,861 0.0% ▲ Add 2 SEC ↗

“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.

New buyers

Citadel Advisors $4.13M 0.0%
Marshall Wace $3.54M 0.0%

Exited

No tracked exits this quarter.

Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 108 holders, 26.83M shares, $592.78M reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.

Frequently co-owned

What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.

Provenance: Ownership from parsed 13F common-stock positions (tracked universe, comparable sets for changes); insider rows from Forms 3/4/5; stakes from Schedules 13D/13G; every filing links to its original on SEC EDGAR. Reporting period: Q4 2024 · Methodology · Get this via the API